Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update

Gossamer Bio, Inc. (NASDAQ:GOSS) was the target of a significant decline in short interest in August. As of August 31st, there was short interest totalling 9,080,000 shares, a decline of 5.2% from the August 15th total of 9,580,000 shares. Based on an average daily volume of 1,990,000 shares, the days-to-cover ratio is currently 4.6 days.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a report on Tuesday. Wedbush reiterated an “outperform” rating and issued a $4.00 target price on shares of Gossamer Bio in a report on Tuesday, August 13th. Oppenheimer initiated coverage on shares of Gossamer Bio in a report on Tuesday, June 25th. They issued an “outperform” rating and a $9.00 target price for the company. Finally, The Goldman Sachs Group restated a “buy” rating and set a $8.00 price target on shares of Gossamer Bio in a research note on Monday, June 17th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $9.20.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GOSS. Sivia Capital Partners LLC acquired a new stake in shares of Gossamer Bio in the first quarter valued at about $29,000. SG Americas Securities LLC acquired a new stake in shares of Gossamer Bio in the first quarter valued at about $34,000. Choreo LLC acquired a new stake in shares of Gossamer Bio in the second quarter valued at about $46,000. Algert Global LLC acquired a new stake in shares of Gossamer Bio in the second quarter valued at about $75,000. Finally, Sequoia Financial Advisors LLC grew its position in shares of Gossamer Bio by 27.2% in the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock valued at $84,000 after purchasing an additional 20,000 shares during the period. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Price Performance

Shares of NASDAQ GOSS opened at $0.96 on Friday. The business’s 50 day moving average price is $0.93 and its 200 day moving average price is $0.92. The firm has a market cap of $217.12 million, a P/E ratio of -0.91 and a beta of 1.95. Gossamer Bio has a 52 week low of $0.45 and a 52 week high of $1.60. The company has a quick ratio of 8.21, a current ratio of 8.21 and a debt-to-equity ratio of 2.42.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings data on Monday, August 12th. The company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The business had revenue of $95.84 million for the quarter, compared to the consensus estimate of $160.00 million. On average, sell-side analysts expect that Gossamer Bio will post -0.33 earnings per share for the current year.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.